NEW YORK (GenomeWeb News) – The National Institutes of Health plans to fund studies aimed at validating genomic and other types of biomarkers for human diseases that affect the liver, kidney, urological tract, digestive and hematologic systems, and endocrine and metabolic disorders, according to a new funding announcement.
These studies also could pursue biomarkers that could be used in addressing diabetes and its complications, and obesity, for which there are few or no biomarkers, or those that are available are invasive or expensive.
Progress toward new biomarkers for these diseases could be used to advance translational research related to the efficacy of treatments and bio-behavioral interventions for a number of diseases, said NIH.
The "Development and Validation of Disease Biomarkers" grants, which will fund research for up to five years but does not set a limit on the funding levels researchers may seek, is funded by the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Nursing Research, and the Office of Dietary Supplements.
These studies could seek diagnostic or predictive markers for: interstitial cystitis/painful bladder syndrome and chronic prostatitis/chronic pelvic pain syndrome; development or progression of benign prostatic hyperplasia with lower urinary tract symptoms; and urologic disorders with overlapping symptoms.
The research also may seek various types of biomarkers for iron and copper accumulation; for disease activity for inflammatory diseases; gastrointestinal disorders; insulin resistance; angiogenesis; transplant rejection; and others.